The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 801–857 of 857
Ji, P., Zheng, J., Li, H., Gao, W., Lin, Y., Wei, J., Yu, S., Zhang, H., & Zheng, Y. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120188
Rentosertib: A TNIK inhibitor in clinical trials for idiopathic pulmonary fibrosis
Meng, S., & Zhao, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45105-8.00015-9
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086 · Cited by 1
“Following tissue injury, LPAR1 activation triggers associated G proteins, inducing fi brosis [123].”
A patent review of LPAR1 antagonists (2010 – present)
Zhao, J., Li, Y. X., Zheng, W., Liu, Y., Yang, Y., Leng, Y., Wei, S., Lou, J., Shang, X., & Tang, D. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2671884
Chen, A., Baccei, C. S., Baccei, J., Broadhead, A. R., Lorrain, K. I., Poon, M. M., Roppe, J. R., Schrader, T. O., Stebbins, K. J., Valdez, L. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01049
Lu, M., Wang, X., Hu, Y., Jia, S., Qi, Y., Jiao, Y., Zhao, J., Wang, X., Zhang, J., & Jiang, D. (2026) · Experimental Dermatology · doi:10.1111/exd.70313 · Cited by 1
“In fibroblasts, LPAR1 and LPAR3 function as the primary LPA receptors [17, 18] and regulate key cellular processes such as proliferation, migration, and resistance to apoptosis [19, 20].”
Autotaxin inhibitors: an updated patent review (2021-present)
Wei, X., Zhao, C., Cao, Z., Tan, Z., & Zhai, X. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2704850
“…and excessive extracellular matrix deposition via the transforming growth factor-beta (TGF-β )/mothers against dec-apentaplegic/small (Smad) signaling pathway and drives fibroblast proliferation through Rho signaling, thereby contributing to the initiation and progression of fibrosis [18,19].”
Maher, T. M., Kaminski, N., Wang, F., Funke-Chambour, M., Wu, C., Hu, Y., Sharma, S., Schafer, P. H., Schaller, M. A., & Horan, G. S. B. (2026) · Respiratory Research · doi:10.1186/s12931-026-03809-w · Cited by 1
A Bioactive Phospholipid Promotes Rapid Lung Progenitor Activation via AP-1Preprint
Klochova, A., Weiner, A. I., Hata, K., Holcomb, N. P., Kass-Gergi, S., Mendoza, M., Martinez, E. A., Abraham, D. M., Staszewski, M. Y., Maiden, M. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741214
Nagata, W., & Takada, K. (2026) · Inflammation Research · doi:10.1007/s00011-026-02337-z
“In lung injury and pulmonary fibrosis mod - els, LPAR1 links tissue injury to fibroblast recruitment and vascular leak [14 ].”
InfluentialZhu, M., Cui, L., Guo, Y., Tu, Y., Wang, Y., Zhou, W., Zhang, Y., Xie, L., & Jin, H. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.10.34
“21 Accordingly, LPA1 expression and fibrotic marker levels were evaluated in hypoxia-exposed ARPE-19 cells.”
Jeong, S.-W., & Im, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167296
“Accumulating evidence indicates that endogenous LPA in the lung functions as a key regulator of pro-inflammatory and profibrotic processes in various murine models of pulmonary disease, including asthma [12,13], pulmonary fibrosis [14], and acute lung injury [15].”
InfluentialNazemi, N., Crestani, B., Helou, D. G., Distler, O., Gote-Schniering, J., Vold, A., Machahua, C., Kolb, M. R. J., & Funke-Chambour, M. (2026) · European Respiratory Journal · doi:10.1183/13993003.00258-2026
“In addition to latent TGF-β 1 activation [140], mediators such as PDGF [141], connective tissue growth factor [142, 143], macrophage colony-stimulating growth factor [144] and lysophosphatidic acid contribute to fibrosis and epithelial cell injury [145, 146].”
Kang, W., Peng, X., Zhou, W., & Zhang, C. (2026) · Journal of Mass Spectrometry · doi:10.1002/jms.70108
Advances in metabolic reprogramming of pulmonary fibrosis
Zhou, H., & Zhang, T. (2026) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2026.07.003
Jeong, J.-H., Kim, B., Ryu, H., Shin, Y., Lee, H. J., Kang, J., Kim, D., Shin, D. H., Park, H., & Park, C. (2026) · Research Square · doi:10.21203/rs.3.rs-10912541/v1
Maher, T. M., Martínez, F. J., Kreuter, M., Corte, T. J., Wijsenbeek, M. S., Ogura, T., Suda, T., Xu, Z., Fischer, A., Wang, Y., et al. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2026-004324
Autotaxin induces fibrosis in lamina cribrosa cells in glaucoma
O’Regan, A., Irnaten, M., Eivers, S., O’Callaghan, J., Wallace, D., & O'Brien, C. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-74457-9
“In idiopathic pulmonary fibrosis (IPF), the lysophosphatidic acid (LPA) axis has been shown to play a major role 10,11 .”
Metabolic reprogramming in pulmonary fibrosis: mechanisms and therapeutic perspectives
Wu, Y., Su, X., Zhou, J., Zheng, S., 冯琼, 庄静英, Yu, Z., Qiu, H., Xia, Y., Wu, J., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1982119
Therapeutic advances in pulmonary fibrosis
Temizel, E., Amaral, A. F., Kaenmuang, P., Logan, N., & Chaudhuri, N. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261489541
BindingDB (2012) · UC San Diego · doi:10.7270/q2gt5nj5
BindingDB Entry 50048009: Discovery of potent inhibitors of the lysophospholipase autotaxin.
BindingDB (2018) · UC San Diego · doi:10.7270/q2dj5hm1
BindingDB (2022) · UC San Diego · doi:10.7270/q2q81hvp
BindingDB Entry 50014961: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
BindingDB (2023) · UC San Diego · doi:10.7270/q2pz5dp9
BindingDB Entry 50009334: Identification of Potent
BindingDB (2021) · UC San Diego · doi:10.7270/q2c82dqx
BindingDB (2017) · UC San Diego · doi:10.7270/q2bz681d
BindingDB (2019) · UC San Diego · doi:10.7270/q29c70v2
BindingDB (2021) · UC San Diego · doi:10.7270/q2gm8bw0
BindingDB Entry 50031981: Discovery and optimization of boronic acid based inhibitors of autotaxin.
BindingDB (2010) · UC San Diego · doi:10.7270/q2g73dxk
BindingDB (2020) · UC San Diego · doi:10.7270/q2xk8j7n
BindingDB (2020) · UC San Diego · doi:10.7270/q2fn1943
BindingDB (2020) · UC San Diego · doi:10.7270/q25141pd
BindingDB Entry 50010452: A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA
BindingDB (2021) · UC San Diego · doi:10.7270/q2df6vsr
BindingDB Entry 50014842: Imaging Autotaxin
BindingDB (2023) · UC San Diego · doi:10.7270/q20p13ws
Valente, M. (2014) · Figshare
BIOLOGICAL FUNCTIONS OF THE NOVEL LYSOPHOSPHATIDIC ACID (LPA) RECEPTOR, LPA4/p2y9/GPR23
Lee, P. (2008) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/89eb-rk89
David, M. (2010) · theses.fr (ABES) · doi:10.70675/ac5b78e8z9194z4a0cza6f5z1c8ec00cbbf7
“Les souris LPAr1 développent moins de fibrose rénale et pulmonaire que les souris sauvages démontrant l’importance de ce récepteur dans ces pathologies [208,209].”
BackgroundContribution of IL-17 to the pulmonary inflammatory response
Couillin, I., Gasse, P., Huaux, F., Schnyder‐Candrian, S., Schnyder, B., Erard, F., Moser, R., & Ryffel, B. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8681-8_9
“Lysophosphatidic acid levels were increased in BAL fluid following bleomycin injury, and mice lacking one of its receptors, LPA1, are markedly protected from fibrosis [ 40 ].”
Background
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.